MedPath

The Efficacy of Treatment for Helicobacter Pylori Infection in Preschooler by Yoghurt With LG21

Not Applicable
Active, not recruiting
Conditions
H. Pylori Infection
Interventions
Dietary Supplement: Meiji Yogurt Group
Registration Number
NCT06045494
Lead Sponsor
Meiji China Investment Co.,Ltd
Brief Summary

The goal of this randomized, open-label, interventional trial is to study the efficacy of treatment for Helicobacter Pylori Infection in Preschooler aged 4-6 by Meiji Yoghurt with LG21. The main question it aims to answer is:

- whether the treatment by Meiji Yoghurt LG21 is effective by stool antigen (HpSA) test

140 qualified participants will be enrolled and randomized into 2 groups of the same size (product study group and blank control group). Participants of the product study group will need to eat assigned Meiji Yoghurt for 12 weeks, one bottle each day, while participants of the blank control group won't receive any intervention during the study. Four visits will be made for all participants, and relevant clinical data will be captured and recorded into CTMS (Clinical Trial Management System) for statistical analysis and reporting.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
140
Inclusion Criteria
  • Preschooler aged 4-6 years
  • H. pylori positive
  • Drink milk or milk beverages regularly (more than three times a week) before joining the study
  • ICF signed
  • Parents or guardians agree not to participate in other interventional clinical studies during this study
Exclusion Criteria
  • Has potential metabolic class or chronic disease
  • Use of antibiotics within 7 days before randomization (as judged by the trial responsible physician)
  • People who have been treated for eradication of Helicobacter pylori
  • Pharmaceuticals, medicinal skin care products (medical external products) and health foods that may affect gastric symptoms have been commonly used since more than one month ago
  • Already under digestive system treatment
  • Has lactose intolerance or protein allergy
  • Those whose families had plans to leave Jinhua City during the study period
  • Fails to comply with the provisions of the protocol
  • Those who are deemed unsuitable as subjects by the physician

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Meiji Yogurt GroupMeiji Yogurt GroupMeiji LG21 yogurt: 180 g/bottle, main ingredients: Raw milk, water, sugar, skim milk powder, food additives (hydroxypropyl distarch phosphate, pectin), cream, whey protein powder, food flavor, Lactobacillus grigi, Lactobacillus bulgaricus, Streptococcus thermophilus.
Primary Outcome Measures
NameTimeMethod
Helicobacter pylori Stool Antigen Testbaseline day 0, day 112

The stool of the participants will be assessed by Helicobacter pylori Stool Antigen Test (HpSA) on the last day of the study. A negative result indicates that participant is infection-free.

Secondary Outcome Measures
NameTimeMethod
Frequency of Defecationbaseline day 0 to day 112

The frequency of defecation of participants each day during the study

Score of Bristol Stool Scalebaseline day 0, day 42, day 84, day 112

The stool of the participants will be assessed by Bristol Stool Scale, type 1 to type 7, mapping to a score from 1 to 7. where 1 to 7 means stools are from hardest to loosest. Normal stools are those in the middle of the chart, in the 3 to 4 range.

Helicobacter pylori Stool Antigen Testday 42, day 84

The stool of the participants will be assessed by Helicobacter pylori Stool Antigen Test (HpSA) on the day 42 and day 84 from the baseline day. A negative result indicates that participant is infection-free.

Trial Locations

Locations (1)

Kaitai Biotech Lab

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath